{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["81(3)"],"submitter":["Benallegue N"],"pubmed_abstract":["<h4>Importance</h4>Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.<h4>Objective</h4>To assess the real-world association of HET as an index treatment compared with MET with disease activity.<h4>Design, setting, and participants</h4>This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who rec"],"journal":["JAMA neurology"],"pagination":["273-282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10862269"],"repository":["biostudies-literature"],"pubmed_title":["Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis."],"pmcid":["PMC10862269"],"pubmed_authors":["Labauge P","Kerbrat A","Heinzlef O","Debouverie M","Rollot F","Olivier G","Moreau T","Casez O","Vukusic S","Francois C","Claire G","Wiertlewski S","Zephir H","Ciron J","Thouvenot E","Papeix C","Cabre P","Celine L","Maillart E","Claire RB","Berger E","Al Khedr A","Bertrand A","Pelletier J","Corinne P","Clavelou P","Defer G","Alexandre P","Magy L","Chantal N","Romain M","Stankoff B","Javier O","Pascal D","Agnes F","Jean-Philippe N","Casey R","De Seze J","OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators","Ines D","Mikael C","Karolina H","Bourre B","Nicolas C","Haifa BN","Benallegue N","Lebrun-Frenay C","Wahab A","Solene M","Laplaud DA","Emmanuelle LP","Jean-Philippe C","Ruet A"],"additional_accession":[]},"is_claimable":false,"name":"Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.","description":"<h4>Importance</h4>Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.<h4>Objective</h4>To assess the real-world association of HET as an index treatment compared with MET with disease activity.<h4>Design, setting, and participants</h4>This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who rec","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-14T18:59:30.422Z","creation":"2025-04-07T08:59:00.033Z"},"accession":"S-EPMC10862269","cross_references":{"pubmed":["38345791"],"doi":["10.1001/jamaneurol.2023.5566"]}}